PHG vs CBLL vs QDEL Stock Comparison

Koninklijke Philips, Ceribell and QuidelOrtho Prices as of Oct 26, 2026 Peers: Industry group
PHG Koninklijke Philips Nv
$26.56 +6.4% 1M -7.9% 1Y
Market cap
$25.07B
P/E
13.6x
Revenue (TTM)
$20.60B
Div. yield
–
Diagnostic Equipment Healthcare
6 wins
CBLL Ceribell, Inc.
$27.03 +14.1% 1M +109.7% 1Y
Market cap
$1.03B
P/E
–
Revenue (TTM)
$101.96M
Div. yield
–
Diagnostic Equipment Healthcare
3 wins
QDEL QuidelOrtho Corp
$13.77 +25.9% 1M -54.9% 1Y
Market cap
$925.81M
P/E
–
Revenue (TTM)
-$211.90M
Div. yield
–
Diagnostic Equipment Healthcare

Head to Head

9 decided of 12

Koninklijke Philips leads on 6 of the 12 questions below (Koninklijke Philips 6, Ceribell 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionPHGCBLLQDELLeader
Larger companyMarket capitalisation $25.07B $1.03B $925.81M PHG
Cheaper on earningsLower P/E, profitable companies only 13.6x -15.7x -0.9x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 13.4x — 18.4x PHG
Faster revenue growthRevenue growth, trailing twelve months +6.1% +31.7% -30.8% CBLL
More profitableNet margin, trailing twelve months 8.9% -64.7% — PHG
Better return on capitalReturn on invested capital 11.5% — — –
Less leveragedLower net debt / EBITDA 1.8x 1.6x — CBLL
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months -7.9% +109.7% -54.9% CBLL
Better 5-year returnAnnualised price return, 5 years -10.8%/yr — -36.4%/yr PHG
Less volatileAnnualised volatility, 1 year 28.8% 52.2% 93.1% PHG
Higher overall scoreMean of the five percentile scores vs peers 80/100 38/100 22/100 PHG

Percentile Scorecard

PHGCBLLQDEL

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisPHGCBLLQDEL
Valuation 98 #6 of 228 21 #180 of 228 45 #126 of 228
Growth 96 #11 of 221 21 #175 of 221 1 #219 of 221
Profitability 96 #10 of 208 37 #132 of 208 –
Financial Health 31 #166 of 239 81 #46 of 239 10 #215 of 239
Shareholder Returns 79 #29 of 137 29 #97 of 137 30 #96 of 137
Overall 80 38 22
  • PHG ranked among 248 companies in Medical Devices and Diagnostics
  • CBLL ranked among 248 companies in Medical Devices and Diagnostics
  • QDEL ranked among 248 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodPHGCBLLQDELSPY
1 month +6.4%+14.1%+25.9% -0.8%
3 months +6.2%+49.1%-18.2% +3.5%
6 months -3.6%+27.9%+12.0% +7.0%
Year to date -1.9%+23.3%-51.8% +12.2%
1 year -7.9%+109.7%-54.9% +13.0%
3 years +43.6%—-77.4% +86.3%
3 years, per year +12.8%—-39.1% +23.1%
5 years -43.6%—-89.6% +68.6%
5 years, per year -10.8%—-36.4% +11.0%
10 years -11.6%—-35.7% +258.0%
10 years, per year -1.2%—-4.3% +13.6%

Risk

MeasurePHGCBLLQDELSPY
Volatility, 1Y 28.8%52.2%93.1% 12.7%
Downside volatility, 1Y 28.8%49.5%100.9% 12.7%
Beta vs S&P 500, 1Y 0.811.212.61 1.00
Return / volatility, 1Y -0.272.10-0.59 1.02
Max drawdown, 5Y -75.6%-63.9%-94.3% -25.4%
From 52-week high -19.3%-2.3%-61.1% -1.8%
52-week high $32.91$27.68$35.38 $779.14
52-week low $23.81$10.92$9.96 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultiplePHGCBLLQDEL
P/E now vs peer median 13.7xmedian 30.6x -15.6xmedian 30.6x -0.9xmedian 30.6x
P/S now vs peer median 1.2xmedian 3.0x 10.1xmedian 3.0x -4.4xmedian 3.0x
EV/EBITDA now vs peer median 8.1xmedian 17.5x -13.5xmedian 17.5x —median 17.5x
P/FCF now vs peer median 5.9xmedian 23.3x -18.9xmedian 23.3x -4.5xmedian 23.3x
P/B now vs peer median 2.0xmedian 2.4x 8.1xmedian 2.4x 0.5xmedian 2.4x
PEG now vs peer median 0.32median 0.87 —median 0.87 0.01median 0.87

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsPHGCBLLQDEL
Revenue $20.60B $101.96M -$211.90M
Gross profit $16.03B $90.65M –
Operating income $2.65B -$69.97M –
Net income $1.39B -$66.00M -$1.05B
Free cash flow $4.34B -$54.72M -$211.20M
R&D $2.00B $22.95M –
EPS (diluted) $1.91 $-1.74 $-15.35
Cash & equivalents $2.04B $32.66M $123.40M
Total debt $9.51B $19.98M $2.89B
Shares (diluted) 962.50M 38.03M 68.30M
Enterprise value $14.18B $436.22M $394.11M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricPHGCBLLQDEL
P/E 13.7x -15.6x -0.9x
P/FCF 5.9x -18.9x -4.5x
P/Operating cash flow 9.6x -19.1x -16.4x
P/S 1.2x 10.1x -4.4x
P/B 2.0x 8.1x 0.5x
P/Tangible book 2.5x 8.1x -1.0x
EV/EBITDA 8.1x -13.5x –
EV/EBIT 12.4x -13.2x –
EV/Revenue 1.6x 9.1x -17.5x
EV/FCF 7.6x -16.9x -17.6x
EV/Operating cash flow 12.4x -17.1x -64.8x
PEG (3Y EPS CAGR) 0.32 – 0.01

Growth

14 metrics
MetricPHGCBLLQDEL
Revenue growth (1Y) 6.1% 31.7% -30.8%
Revenue CAGR (3Y) 2.3% – -27.0%
Gross profit growth (1Y) 82.4% 33.4% –
Gross profit CAGR (3Y) 6.7% – –
Operating income growth (1Y) 121.3% -34.6% –
Operating income CAGR (3Y) 52.0% – –
Net income growth (1Y) 293.5% -33.6% -124.8%
Net income CAGR (3Y) 35.6% – -107.7%
EPS growth (1Y) 539.4% -27.5% -122.8%
EPS CAGR (3Y) 42.2% – -106.5%
Operating cash flow growth (1Y) 116.7% -44.3% -128.5%
Operating cash flow CAGR (3Y) 53.6% – -27.1%
Free cash flow growth (1Y) 54.2% -41.8% -1,725%
Free cash flow CAGR (3Y) 45.6% – -30.1%

Profitability

14 metrics
MetricPHGCBLLQDEL
Gross margin 77.8% 88.9% –
EBITDA margin 19.8% -67.1% –
Operating margin 12.9% -68.6% –
Pretax margin 11.9% -64.7% –
Net margin 8.9% -64.7% –
FCF margin 21.1% -53.7% –
Operating cash flow margin 12.9% -53.0% 27.0%
Return on equity 12.7% -49.0% –
Return on assets 5.4% -38.3% –
Return on invested capital 11.5% – –
Return on capital employed 11.8% -45.1% –
Asset turnover 0.7x 0.6x 0.0x
Cash conversion (OCF / net income) 1.9x 0.8x 0.1x
Stock comp / revenue 0.7% 16.1% -20.9%

Financial Health

11 metrics
MetricPHGCBLLQDEL
Debt / assets 31.2% 12.0% 50.6%
Debt / equity 0.7x 0.2x 1.6x
Net debt / EBITDA 1.8x 1.6x –
Debt / FCF 2.2x -0.4x -13.7x
Liabilities / assets 57.1% 22.9% 68.9%
Equity / assets 42.9% 77.1% 31.1%
Interest coverage 6.2x -38.6x –
Current ratio 1.3x 9.2x 1.4x
Quick ratio 0.7x 8.6x 0.5x
Cash ratio 0.2x 7.5x 0.1x
Altman Z-score – 14.35 –

Shareholder Returns

7 metrics
MetricPHGCBLLQDEL
Dividend yield 3.7% – –
Net buyback yield -0.5% -0.6% -0.6%
Shareholder yield 3.3% -0.6% -0.6%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusPHGCBLLQDEL
Forward P/E 13.4xFY2026 – 18.4xFY2026
EPS, next fiscal year $1.98FY2026 $-1.86FY2026 $0.75FY2026
EPS growth, next FY +6.5%FY2026 – -64.6%FY2026
EPS growth, the year after -10.1% – +101.3%
Revenue, next fiscal year $21.63BFY2026 $118.32MFY2026 $2.67BFY2026
Revenue growth, next FY +1.8%FY2026 +32.9%FY2026 -2.0%FY2026
Revenue growth, the year after -8.2% +21.1% +0.2%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersPHGCBLLQDEL
Held by institutions 5.4% 79.9% 100.0%
Institutions holding 363 124 243
Change in shares held, QoQ +0.8% +2.2% +2.9%
Institutions buying 266 74 143
Institutions selling 76 36 65
Buyers to sellers 3.50 2.06 2.20

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

PHGCBLLQDEL
PHG 1.00 0.22 0.24
CBLL 0.22 1.00 0.26
QDEL 0.24 0.26 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, PHG, CBLL and QDEL?

Koninklijke Philips (PHG) is the largest by market capitalisation: Koninklijke Philips (PHG) $25.07B, Ceribell (CBLL) $1.03B, QuidelOrtho (QDEL) $925.81M.

Which company is growing faster?

Ceribell (CBLL) grew revenue fastest over the trailing twelve months: Koninklijke Philips (PHG) +6.1%, Ceribell (CBLL) +31.7%, QuidelOrtho (QDEL) -30.8%.

Which company is more profitable?

Koninklijke Philips (PHG) has the highest net margin (Koninklijke Philips (PHG) 8.9%, Ceribell (CBLL) -64.7%).

Which stock has performed better?

Over the past year Ceribell (CBLL) returned the most: Koninklijke Philips (PHG) -7.9%, Ceribell (CBLL) +109.7%, QuidelOrtho (QDEL) -54.9%. Over five years, Koninklijke Philips (PHG) compounded fastest (Koninklijke Philips (PHG) -10.8%/yr, QuidelOrtho (QDEL) -36.4%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Koninklijke Philips (PHG) has been the steadiest (Koninklijke Philips (PHG) 28.8%, Ceribell (CBLL) 52.2%, QuidelOrtho (QDEL) 93.1%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, PHG, CBLL and QDEL?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Koninklijke Philips (PHG) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.